Pharmaceuticals, Biotechnology & Life Sciences

AbbVie boosts share count by 20,000 at $219.76, keeping prices steady, while partnering Neurocrine and adding Dr. Ratz to accelerate biologics and device‑based therapies—enhancing pipeline depth and future capital flexibility.

Discover how Sartorius AG’s bioprocess‑centric strategy fuels 8‑11% growth and rising margins, and why investors rally amid biotech trends.

Discover how Bayer’s new renal‑cardio drug and contrast‑media expansion is reshaping investor sentiment, boosting earnings, and positioning the company for long‑term growth.

Merck KGaA’s 2½% share‑price rise shows investors bet on its dual‑stream strategy: high‑growth MS therapies with pay‑for‑performance access and a resilient copper‑sulfate chemical division poised for battery demand.

FTC eyes drug makers as key patents expire, aiming to cut price spikes and speed generic entry while protecting innovation.

Johnson & Johnson’s recent share dip is linked to FTC scrutiny over Darzalex’s patent expiration, highlighting regulatory risks and the firm’s R&D‑driven turnaround strategy.

Galderma Group AG’s growth hinges on its aesthetic dermatology focus, R&D strides, and digital/sustainability opportunities—watch how regulatory shifts and competition shape its Swiss market rise.

Amgen’s strong financials and pipeline position it to capture 5–7 % of the $30 bn GLP‑1 market by 2035, offering investors a growing upside amid rising diabetes and obesity rates.

Eurofins Scientific’s March 2026 share‑buyback shows strong financial discipline and confidence, while its solid margins and low debt support future innovation in diagnostic services.

Roche’s new CE‑marked Elecsys ApoE4 blood test offers rapid, highly accurate genetic risk for Alzheimer’s, fitting seamlessly into existing Elecsys platforms and paving the way for personalized, cost‑effective care.